Cardiawave

Cardiawave is a French medtech company that focuses on developing non-invasive ultrasound therapy for treating calcific aortic stenosis, a serious heart valve disease. Founded in 2014 by physicists and cardiologists from top French research institutions, Cardiawave aims to provide an innovative alternative to traditional surgical treatments. The company's main product, the Valvosoft® platform, utilizes focused ultrasound to soften calcified aortic valve leaflets without the need for surgery or valve replacement. This approach is particularly beneficial for patients who cannot undergo conventional surgical aortic valve replacement or transcatheter aortic valve replacement. Cardiawave has conducted several clinical studies across Europe, showing promising results in safety and efficacy, including significant improvements in patient quality of life and valve function. Cardiawave targets cardiologists, hospitals, and healthcare providers who treat elderly patients with severe symptomatic aortic stenosis. The company is committed to enhancing patient outcomes and reducing the healthcare burden associated with invasive surgeries.

• Employees 27
• Founded 2014
• Total Funding $9670977